"Through its Phase I/IIb EXCELLENT clinical trial, CellProthera, a France-based biotechnology research company focusing on cardiac tissue regeneration, is demonstrating the safety and efficacy of a cell therapy approach to regenerating tissue following myocardial infarction. Here, CEO Matthieu de Kalbermatten shares his ambition to fulfil the promise of stem cell research"...
Investment landscape In 2023, Matthieu de Kalbermatten, CEO of CellProthera, looks forward to presenting the final safety and efficacy results of the company’s Phase II clinical trial, and for moving into Phase III. He says "Significantly, there is a new scheme set up in France whereby innovative biotherapies that address unmet medical needs can enter the market following a successful Phase II clinical, while running a Phase III in parallel. This will give us the opportunity to open dialogues with the regulatory body and gain invaluable experience in the marketing of our CGT product." For the industry, especially in Europe, initiatives and government regulatory reforms represent a great opportunity for companies such as CellProthera to bring their therapies to patients more easily. De Kalbermatten says the accelerated regulatory pathways will be key to getting more CGTs to market, however, in order to make it to approval pathways, many start-ups and smaller biotechs need to secure investments. He says: “The investment landscape has been tough this year and that looks to be carrying over into 2023. However, there is solid hope that the situation should come back to normal by the end of 2023 according to the usual 'up and down' cycle in the industry.”
Posted in DDW Exclusive Content, Market Reports | Tagged Advanced Therapy Medicinal Products (ATMPs), Alliance for Regenerative Medicine, Cell and gene therapy, EFPIA, EU, European Commission, European Federation of Pharmaceutical Industries and Associations, Market reporting
[video width="1920" height="1080" mp4="https://www.cellprothera.com/wp-content/uploads/2022/12/2022-09-29_BFM-Tech-co_SUBEN.mp4"][/video] BFM BUSINESS - TECH & CO 29 September 2022...
[video width="1920" height="1080" mp4="https://www.cellprothera.com/wp-content/uploads/2022/12/2022-09-29_France5-Mag-Sante_SUBEN.mp4"][/video] France 5 29 September 2022...
You are looking for an Internship of 6 months to Actively support on a day to day...
France 3 - Ile de France 15 July 2022...
[video width="1920" height="1080" mp4="https://www.cellprothera.com/wp-content/uploads/2022/12/2022-02-03_Cellprothera-BFM-Business-EN.mp4"][/video] BFM BUSINESS - France that resists 2 February 2022...
[video width="1920" height="1080" mp4="/wp-content/uploads/2021/11/BFM-Business-Cellprothera_Matthieu-de-Kalbermatten_2021.mp4" type="video/mp4"][/video] BFM BUSINESS - La Pépite Interview de Matthieu de Kalbermatten 9 November 2021...
On World Heart Day 2021, let's remember that heart disease, including heart attacks, remains the leading cause of death worldwide. The CellProthera team is proud to contribute to the global effort to treat heart attack patients with cell therapy.